Importation
-
Initial Take on MFN Executive Order, Part II
Read more: Initial Take on MFN Executive Order, Part IIInitial take at 3:30 today … which could change as I learn more… The foundational premise of the President’s new Executive Order (EO) is that the United States should pay less for drug and other countries should pay more; there should be an equalization. The Administration will take steps to work with foreign countries and…
-
340B, Biosimilars, CMMI, Drug Prices, Generics, Healthcare Costs, Importation, Insulin, Medicaid, Pharmacy Benefit ManagersDon’t Call it a Comeback
Read more: Don’t Call it a ComebackLet’s wrap up my musings on the President’s Executive Order (EO). Medicaid. Section 6 of the EO directs the Office of Management and Budget (OMB) Director, the Assistant to the President for Domestic Policy, and the Assistant to the President for Economic Policy, in coordination with the Secretary of Health and Human Services (HHS), to…
-
340B, Biosimilars, Caught my eye, Employers, Importation, Obesity, Pharmacy Benefit Managers, State-based ReformCaught my eye — 03/15/24
Read more: Caught my eye — 03/15/24It was one of those rare weeks in Washington, DC where the weather was just perfect. I mean not if you suffer from allergies, but for everyone else. Same Same. Last week we had the State of the Union, this week we had the President’s Budget release. For what it is worth, the budget is…
-
Caught my eye — 12/8/23
Read more: Caught my eye — 12/8/23Marching right past. Senator Bernie Sanders held up the head of the NIH hearings because he wanted to make sure march-in rights were part of the policy conversations on drug pricing. I can’t decide if march-in rights are like your 1st grade teacher asking for part of your salary because she was part of your…
Latest news
- Caught my eye — 5/16/25
- Initial Take on MFN Executive Order, Part II
- Caught my eye — 5/09/25
- Don’t Call it a Comeback
- Caught my eye — 5/2/25
Categories
- 340B (38)
- Affordable Care Act (5)
- Alzheimer's (6)
- Biosimilars (22)
- Caught my eye (67)
- Cell and Gene (2)
- Chevron Deference (2)
- CMMI (14)
- Copay Accumulators (6)
- COVID (2)
- Drug Prices (36)
- Drug shortages (10)
- DTC (2)
- Employers (8)
- Generics (6)
- Health Equity (3)
- Healthcare Costs (30)
- ICER (10)
- Importation (4)
- Inflation Reduction Act (50)
- Insulin (5)
- IP (3)
- Long term care (1)
- Medicaid (7)
- Medicare Advantage (16)
- Medicare Negotiation (52)
- Medicare Part D (47)
- Medicare Transaction Facilitator (3)
- Medicare Transaction Facilitator (9)
- Obesity (21)
- On the Horizon (1)
- Orphan Drugs (3)
- Pharmacy Benefit Managers (32)
- Preventative (2)
- Reference Pricing (8)
- State-based Reform (16)
- Supply Chain (2)
- Uncategorized (7)
- Utilization Management (1)
- Vaccines (4)
- Value (13)